Prophylactic antibiotic use could halve post-birth maternal infections, study indicates
May 14, 2019Manufacturing and Production, Research and Development Antibiotics, University of Oxford, pharma
A study led by researchers at the University of Oxford has argued that the administration of preventative antibiotics to all …
FDA expands indication for Eylea to cover all stages of diabetic retinopathy
May 14, 2019Manufacturing and Production Bayer, Eylea, FDA, Regeneron, approval, pharma
The FDA has expanded the indication for Regeneron’s Eylea (aflibercept) to include all stages of diabetic retinopathy. Regeneron chief scientific …
Mental health spending varies dramatically among regions in England, analysis shows
May 14, 2019Manufacturing and Production England, NHS, UK, mental health, mind, spending
Spending on mental health varies dramatically between regions in England, according to analysis from mental health charity Mind. South Yorkshire …
MSD’s Keytruda recommended on NHS in Scotland for Stage 3 melanoma
May 14, 2019Manufacturing and Production, Sales and Marketing Cancer, MSD, Scotland, Scottish Medicines Consortium, keytruda, melanoma, pharma
MSD has revealed that Keytruda (pembrolizumab) will be made available to NHS Scotland patients after the Scottish Medicines Consortium (SMC) …
Chinese pharmaceuticals will not be subject to tariffs, US Trade Representative says
May 14, 2019Manufacturing and Production China, US, USTR, pharma, tariffs, trade
The Office of the United States Trade Representative (USTR) has said pharmaceuticals will not be subject to potential US tariffs …
The interplay between the GDPR and the EU Clinical Trials Regulation
May 13, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GDPR, clinical trial data, clinical trials, eu clinical trials regulation, pharma, trial data
Paul Kavanagh, partner at law firm Dechert, explores the relationship between GDPR and CTR, and its potential impact on the …
UK GPs are underequipped to handle growing chronic opioid use, report warns
May 13, 2019Medical Communications, Sales and Marketing NHS, UK, opioid crisis, opioids, pharma
New research from the University of East Anglia (UEA) has argued that general practitioners (GPs) in the UK are lacking …
US sees 300% increase in the number of cases of Hepatitis A
May 13, 2019Sales and Marketing CDC, hepatitis a, pharma, public health, sanitation
The number of Americans infected with Hepatitis A has increased 300% in the past three years, according to figures from …
Heart disease deaths increase for first time in 50 years
May 13, 2019Sales and Marketing BHF, UK, cardiovascular, health, heart disease, obesity
Deaths from heart disease among people under the age of 75 have increased for the first time in 50 years. …
Lilly’s Cyramza approved in US for hepatocellular carcinoma sub-population
May 13, 2019Sales and Marketing Eli Lilly, FDA, cyramza, hepatocellular carcinoma, pharma
Eli Lilly’s vascular endothelial growth factor (VEGF) receptor 2 antagonist Cyramza (ramucirumab) has received approval in the US as a …
US States allege 20 generic drugmakers fixed prices of generic drugs
May 13, 2019Sales and Marketing competition, generics, markets, price fixing, price-fixing, pricing
Forty-four US States have filed a lawsuit against 20 generic drugmakers – including Teva Pharmaceuticals – over allegations the firms …
FDA to end controversial “alternative summary reporting” of medical devices in bid to boost transparency
May 10, 2019Medical Communications, Research and Development, Sales and Marketing FDA, US, adverse events, medical devices, pharma
The FDA has revealed that it plans to terminate its “alternative summary reporting” programme which has allowed the manufacturers of …
Top Ten most popular articles on Pharmafile.com this week!
May 10, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, GSK, Innoviva, NHS, Novartis, health, migraine, pharma
This week was a particularly bad one for the NHS after it was revealed thousands of EU nurses were leaving …
Clinical trial will test long acting HIV injection
May 10, 2019Medical Communications Art, CAB, HIV, Janssen, RPV, ViiV, injectable
A long-acting, injectable HIV drug combo is to be tested in a clinical trial of 350 volunteers with HIV. The …
BMS blockbuster Opdivo falls short at Phase 3 in MGMT-unmethylated glioblastoma multiforme
May 10, 2019Medical Communications, Research and Development BMS, Bristol-Myers Squibb, glioblastoma multiforme, pharma, trial failure
Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) has hit a hurdle, failing its primary endpoint in a Phase 3 trial investigating …
Gilead will give 11 years’ worth of PrEP drugs to those at risk of HIV after ‘discussions’ with Trump
May 10, 2019Medical Communications Gilead, HIV, PrEP, Trump, Truvada, descovy
Gilead Sciences has agreed to donate 11 years’ worth PrEP drugs for up to 200,000 individuals each year, following “discussions …
Ocrevus becomes first NICE-approved therapy on the NHS for primary progressive multiple sclerosis
May 9, 2019Sales and Marketing Genentech, NHS, NICE, Ocrevus, UK
NICE has announced its final appraisal decision on Genentech’s Ocrevus (ocrelizumab), choosing to recommend the drug for use on the …
Thousands of EU nurses and midwives leave NHS because of Brexit
May 9, 2019Medical Communications NHS, health, hospitals, midwifes, nurses
Nearly 5,000 EU nurses and midwifes have left the NHS over the past two years. The number of EU nationals …
Novartis buys dry eye treatment Xiidra in deal worth $5.3 billion
May 9, 2019Business Services, Medical Communications, Sales and Marketing Novartis, Shire, Takeda, debt, pharma, xiidra
Japanese multinational Takeda Pharmaceutical has agreed to sell its dry eye drug Xiidra to Swiss firm Novartis in a deal …
Sanofi’s Dupixent approved in Europe for severe asthma maintenance
May 9, 2019Sales and Marketing Dupixent, EU, Europe, Sanofi, asthma, pharma
Sanofi has revealed that its interleukin-4 and interleukin-13 (IL-4 and IL-13) inhibitor Dupixent (dupilumab) has been awarded marketing approval by …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
